Treat-and-Extend Therapy Using Aflibercept for Neovascular Age-Related Macular Degeneration: A Prospective Clinical Trial REPLY

被引：0
|
作者：
Decroos, Francis Char
Reed, David
Adam, Murtaza K.
Salz, David
Gupta, Omesh P.
Ho, Allen C.
Regillo, Carl D.
机构：
来源：
AMERICAN JOURNAL OF OPHTHALMOLOGY | 2017年 / 182卷
关键词：
D O I：
暂无
中图分类号：
R77 [眼科学];
学科分类号：
100212 ;
摘要：
引用
收藏
页码：205 / 206
页数：2
相关论文
共 50 条
  • [21] Macular Atrophy in Neovascular Age-Related Macular Degeneration with Monthly versus Treat-and-Extend Ranibizumab
    Abdelfattah, Nizar S.
    Al-Sheikh, Mayss
    Pitetta, Sean
    Mousa, Ahmed
    Sadda, SriniVas R.
    Wykoff, Charles C.
    OPHTHALMOLOGY, 2017, 124 (02) : 215 - 223
  • [22] A modified treat-and-extend regimen of aflibercept for treatment-na⟨ve patients with neovascular age-related macular degeneration
    Ohnaka, Masayuki
    Nagai, Yoshimi
    Sho, Kenichiro
    Miki, Katsuaki
    Kimura, Motoki
    Chihara, Tomoyuki
    Takahashi, Kanji
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2017, 255 (04) : 657 - 664
  • [23] Twelve-Month Outcomes of "Treat and Extend" aflibercept Therapy for Neovascular Age-Related Macular Degeneration
    Barthelmes, Daniel
    Vuong Nguyen
    Arnold, Jennifer
    McAllister, Ian
    Guymer, Robyn
    Essex, Rohan
    Young, Stephanie
    Gillies, Mark C.
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2016, 57 (12)
  • [24] A modified treat-and-extend regimen of aflibercept for treatment-naïve patients with neovascular age-related macular degeneration
    Masayuki Ohnaka
    Yoshimi Nagai
    Kenichiro Sho
    Katsuaki Miki
    Motoki Kimura
    Tomoyuki Chihara
    Kanji Takahashi
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2017, 255 : 657 - 664
  • [25] TREAT-AND-EXTEND BEVACIZUMAB FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION The Importance of Baseline Characteristics
    Rush, Ryan B.
    Simunovic, Matthew P.
    Vandiver, Lorelei
    Aragon, Antonio V., II
    Ysasaga, Jason E.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2014, 34 (05): : 846 - 852
  • [26] Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration
    Yuma Tsunekawa
    Keiko Kataoka
    Keiko Asai
    Yasuki Ito
    Hiroko Terasaki
    Japanese Journal of Ophthalmology, 2021, 65 : 69 - 76
  • [27] Four-year outcome of aflibercept administration using a treat-and-extend regimen in eyes with recurrent neovascular age-related macular degeneration
    Tsunekawa, Yuma
    Kataoka, Keiko
    Asai, Keiko
    Ito, Yasuki
    Terasaki, Hiroko
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2021, 65 (01) : 69 - 76
  • [28] TWO YEAR OUTCOMES OF "TREAT AND EXTEND" INTRAVITREAL THERAPY USING AFLIBERCEPT PREFERENTIALLY FOR NEOVASCULAR AGE-RELATED MACULAR DEGENERATION
    Barthelmes, Daniel
    Vuong Nguyen
    Daien, Vincent
    Campain, Anna
    Walton, Richard
    Guymer, Robyn
    Morlet, Nigel
    Hunyor, Alex P.
    Essex, Rohan W.
    Arnold, Jennifer J.
    Gillies, Mark C.
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2018, 38 (01): : 20 - 28
  • [29] Comparison of two different treat-and-extend protocols with aflibercept in wet age-related macular degeneration
    Taipale, Claudia
    Lindholm, Juha-Matti
    Laine, Ilkka
    Tuuminen, Raimo
    ACTA OPHTHALMOLOGICA, 2020, 98 (03) : 267 - 273
  • [30] Efficacy of Intravitreal Aflibercept Treat-and-Extend Regimen Over 2 Years for Neovascular Age-Related Macular Degeneration: ARIES Study
    Souied, Eric H.
    Holz, Frank G.
    Hykin, Philip G.
    Midena, Edoardo
    Wolf, Sebastian
    Allmeier, Helmut
    Mitchell, Paul
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2020, 61 (07)
12345